| Identification | Back Directory | [Name]
FOXY-5 | [CAS]
881188-51-8 | [Synonyms]
FOXY-5
Foxy-5(Wnt5a peptide mimetic)
Foxy 5
Discontinued
(see F746005)
L-Leucine, N-formyl-L-methionyl-L-α-aspartylglycyl-L-cysteinyl-L-α-glutamyl-
N-formyl-L-methionyl-L-alpha-aspartyl-glycyl-L-cysteinyl-L-alpha-glutamyl-L-leucine | [Molecular Formula]
C26H42N6O12S2 | [MDL Number]
MFCD30182296 | [MOL File]
881188-51-8.mol | [Molecular Weight]
694.77 |
| Chemical Properties | Back Directory | [Boiling point ]
1244.1±65.0 °C(Predicted) | [density ]
1.368±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
3.34±0.10(Predicted) | [color ]
White to off-white | [Sequence]
{For}-Met-Asp-Gly-Cys-Glu-Leu | [InChIKey]
WFZPJYYCTSHDJI-KMTCJHMQNA-N | [SMILES]
[C@H](CCC(=O)O)(C(=O)N[C@H](C(=O)O)CC(C)C)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC=O)CCSC |&1:0,9,20,30,38,r| |
| Hazard Information | Back Directory | [Uses]
Foxy 5 is a Wnt-5a-derived hexapeptide, which inhibits breast cancer metastasis in vivo by targeting cell motility. | [Definition]
ChEBI: (2S)-2-[[(2S)-4-carboxy-2-[[(2R)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-formamido-4-(methylthio)-1-oxobutyl]amino]-1-oxopropyl]amino]-1-oxoethyl]amino]-3-mercapto-1-oxopropyl]amino]-1-oxobutyl]amino]-4-methylpentanoic acid is a peptide. | [in vivo]
Foxy-5 (2 mg/kg intraperitoneally injected 9 times a day for 7-23 days) reduces the number of colon cancer stem cells in a mouse model of human colon cancer xenotransplantation[2].
Foxy-5 (2 mg/kg, intraperitoneal injection, once a day, for 3-9 weeks) significantly reduces the early metastasis and spread of WNT5A low DU145 prostate cancer cells in a mouse model of prostate cancer xenotransplantation[3].
| Animal Model: | A Xenograft Mouse Model of Human Colonic Cancer[2] | | Dosage: | 2 mg/kg | | Administration: | i.p. 9 times a day for 7-23 days | | Result: | Reduced the expression of ALDH, DCLK1 and COX-2.
Increased the expression of 15-PGDH.
Reduced the expression of the downstream β-catenin target ASCL2.
|
| Animal Model: | A Xenograft Mouse Model of Prostate Cancer [3] | | Dosage: | 2 mg/kg | | Administration: | i.p. once a day, for 3-9 weeks | | Result: | Reduced metastatic spread and the number of tumor cells in lymph nodes. |
| [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|